Endocrine Abstracts

Thyroid hormones (TH), among their pleiotropic actions, play a central role in the regulation of metabolism and in cognitive functions. Indeed, hypothyroidism is associated with a decrease in energy expenditure and lipid metabolism, and an impairment of memory. Metabolic deregulations induced by a high fat diet (HFD) generate peripheral inflammation, which promotes the development of neuroinflammation in various brain regions. This inflammatory state can disrupt neuronal homeo...

Introduction: Osilodrostat is the newest approved steroidogenic inhibitor drug for the treatment of Cushing’s syndrome (CS). In this presentation, we describe 3 patients who experienced an unexpectedly prolonged adrenal insufficiency following interruption of this treatment.Methods: A monocentric retrospective analysis (October 2019 to January 2023) of ACTH-dependent CS patients controlled with Osilodrostat was performed to identify patients with pr...

Introduction: Osilodrostat and Metyrapone are two CYP11B1 inhibitors used for the treatment of patients with Cushing syndrome. Despite their common suspected mechanism of action, the comparison of serum steroid profiles determined in HPLC-MS/MS in patients treated by either Osilodrostat or Metyrapone for an ACTH-dependent Cushing syndrome identified higher levels of 11-deoxycortisol and androgens in patients treated by Metyrapone than in those treated by Osilodrostat (F. B...

Background: In-patients inadequate food intake can worsen the prevalence and degree of malnutrition.Patients and methods: A “one day” questionnaire was used in medicine (M-Dpts) geriatric (G-Dpts) and surgery (S-Dpts) departments of a university hospital to: i) evaluate nutritional status with the Detky score, ii) quantify food intake, iii) understand the reasons of non-consumption of in-patients (n 286, 46 & 104 in M-, G- & S-Dpts, res...

Introduction: Osilodrostat is a new 11 ß-hydroxylase inhibitor with a mode of action analogue to metyrapone. It has become increasingly used in recent years for treatment of Cushing’s Syndrome (CS). However, few in vivo studies are currently available to accurately compare both drugs characteristics. The objective of our study was to compare steroidogenic profiles in patients treated by either Osilodrostat or Metyrapone for ACTH-dependent CS.Me...

Introduction: Biological diagnosis of Cushing syndrome relies on three parameters: 24 hours-free urinary cortisol; serum cortisol after 1 mg dexamethasone suppression test; late-night serum or salivary cortisol. These tests allow the diagnosis of cortisol excess but do not help in etiological diagnosis, particularly in the distinction between pseudo-Cushing and ACTH-dependent Cushing syndrome, which is often challenging. The aim of this study was to evaluate the performances o...

Context: Craniopharyngiomas are often associated with an unfavorable prognosis but data on their long-term consequences are sparse.Objective: To identify markers of recurrence and factors associated with compromised social rehabilitation and altered quality of life (QoL) in a large cohort of patients with either childhood onset (CO) or adult onset (AO) craniopharyngioma.Methods: Retrospective analysis was performed for 171 patients...

Introduction: The steroidogenesis inhibitor osilodrostat (OSI), indicated for the medical treatment of endogenous Cushing’s syndrome, exhibits significant interindividual variability regarding the response to treatment (Pivonello et al. 2020). Plasma exposure may contribute to this variability. Our objective was to investigate the effect of concomitant use of mitotane (MIT), a potent inducer of CYP450 (3A4), on circulating OSI concentrations in patients treated f...